Supplement Figures:

**Figure S1**: Miriad (TM) multiplexed investigational point-of-care test device
Figure S2: Flow of participants in Mumbai

All consenting patients with suspected HIV, HBV, HCV or Syphilis infection (N=500)

Dropped out and did not provide consent after the study procedure was explained (N=125)

Miriad™ test performed by physician and phlebotomist (N=375)

Blood sample collected for confirmatory testing (N=375)

Post-test combined counseling with key information on four infections, prevention and benefits of early diagnosis (N=375)

Exit interview through administration of semi-structured questionnaire; follow-up visit arranged to disclose confirmatory test results (N=375)

Patients lost to follow up – did not complete their second visit (N=52)

Confirmatory test result communicated (N=323)
**Figure S3: Flow of participants in Montreal**

Number of participants approached (N=155)

All consenting patients with suspected HIV, HBV, HCV or Syphilis infection (N=118)

Miriad™ test performed by research nurse (N=109)

Blood sample collected for confirmatory testing (N=109)

Post-test combined counseling with key information on four infections, prevention and benefits of early diagnosis (N=109)

Exit interview through administration of semi-structured questionnaire; follow-up visit arranged to disclose confirmatory test results (N=109)

Confirmatory test result communicated (N=109)